Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report  

作　　者：Jing-Hao Zhou Qi-Jun Yi Ming-Yan Li Yan Xu Qi Dong Cong-Ying Wang Hai-Yan Liu 

机构地区：[1]Department of Oncology,The Second Affiliated Hospital of Shandong First Medical University,Tai’an 271000,Shandong Province,China

出　　处：《World Journal of Clinical Cases》2024年第4期820-827,共8页世界临床病例杂志

基　　金：Supported by the Science and Technology Innovation Development Project of Tai’an,No.2021NS160;the Medical and Health Science and Technology Development Plan of Shandong Province,No.202102010647。

摘　　要：BACKGROUND Human epidermal growth factor receptor-2(HER-2)plays a vital role in tumor cell proliferation and metastasis.However,the prognosis of HER2-positive gastric cancer is poor.Inetetamab,a novel anti-HER2 targeting drug independently developed in China,exhibits more potent antibody-dependent cell-mediated cytotoxicity than trastuzumab,which is administered as the first-line treatment for HER2-positive gastric cancer in combination with chemotherapy.In this case,the efficacy and safety of inetetamab combined with tegafur was investigated as a second-line treatment for HER2-positive gastric cancer.CASE SUMMARY A 52-year-old male patient with HER2-positive gastric cancer presented with abdominal distension,poor appetite,and fatigue two years after receiving six cycles of oxaliplatin combined with tegafur as first-line treatment after surgery,followed by tegafur monotherapy for six months.The patient was diagnosed with postoperative recurrence of gastric adenocarcinoma.He received 17 cycles of a combination of inetetamab,an innovative domestically developed anti-HER2 monoclonal antibody,and tegafur chemotherapy as the second-line treatment(inetetamab 200 mg on day 1,every 3 wk combined with tegafur twice daily on days 1–14,every 3 wk).Evaluation of the efficacy of the second-line treatment revealed that the patient achieved a stable condition and progression-free survival of 17 months.He tolerated the treatment well without exhibiting any grade 3-4 adverse events.CONCLUSION Inetetamab combined with chemotherapy for the treatment of metastatic HER2-positive gastric cancer demonstrates significant survival benefits and acceptable safety.

关 键 词：Inetetamab Gastric cancer Human epidermal growth factor receptor-2 protein TEGAFUR Case report 

分 类 号：R737.9[医药卫生—肿瘤]